{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-180889","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.869929+00:00","generated_at":"2026-05-17T13:18:45.609819+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Inhibikase Q2 net loss $9.9M; Phase 2b IKT-001 PAH trial to start H2 2025","bullets":["Cash and marketable securities $87.7M at June 30, 2025, vs $97.5M at Dec 31, 2024.","Net loss $9.9M ($0.11/share) for Q2 2025 vs $5.0M ($0.66/share) in Q2 2024.","R&D expenses $5.3M in Q2 2025, up from $3.1M in Q2 2024; SG&A $5.9M vs $2.0M.","Phase 2b IMPROVE-PAH study of IKT-001 (prodrug of imatinib) to begin H2 2025.","Primary endpoint: change in pulmonary vascular resistance at Week 26; secondary include 6MWD."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-180889","json":"https://secwatch.observer/filing/0001193125-25-180889.json","markdown":"https://secwatch.observer/filing/0001193125-25-180889.md","text":"https://secwatch.observer/filing/0001193125-25-180889.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312525180889/0001193125-25-180889-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312525180889/d946023d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:18:45.609819+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}